<DOC>
	<DOCNO>NCT02742623</DOCNO>
	<brief_summary>This study aim collect patient report outcomes assess treatment satisfaction active cancer patient treat rivaroxaban VTE ( venous thromboembolism ) .</brief_summary>
	<brief_title>A Non-interventional Study Xarelto Treatment Venous Thromboembolism ( VTE ) Prevention Recurrent VTE Patients With Active Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult female male patient active cancer fully treat basalcell squamouscell carcinoma skin ( active cancer define diagnosis treatment cancer previous &lt; 6 month recurrent metastatic cancer ) Patients treated standard care anticoagulation ( Low Molecular Weight Heparin / Vitamin K Antagonist ) treatment DVT and/ PE ( index VTE event ) and/ prevention recurrent DVT PE least 4 week prior inclusion study Patients decision make start rivaroxaban treatment DVT and/ PE and/ prevention recurrent DVT PE Patients Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 2 Patients willing participate study ( sign inform consent ) Patients available followup life expectancy &gt; 6 month The contraindication accord local marketing authorization must consider Patients develop index VTE event despite chronic anticoagulant therapy Patients receive apixaban , edoxaban dabigatran investigational drug initial therapy index VTE event Patients participate investigational program intervention outside routine clinical practice exception oncology investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Deep Venous Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
</DOC>